1. Hungary Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Chemical Works of Gedeon Richter Plc

Chemical Works of Gedeon Richter Plc

13,170.00
HUF
+510.00
(+4.03%)
1.83TMarket Cap
Nov 10Next Earn
Chemical Works of Gedeon Richter Plc
BUD:RICHTER
(Budapest Stock Exchange)

Recent

price

13,170.00

P/E

ratio

- -

div

yld

7.14%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HUF
1,478.9
1,655.12
1,763.89
1,891.95
1,911.85
1,971.11
2,096.82
2,386.18
2,391.04
2,729.91
3,047.66
3,390.15
4,308.17
4,357.65
4,685.63
5,080.24
- -
Revenue per Share
347.23
264.94
265.85
229.94
134.86
290.7
356.21
47.71
189.72
253.4
562.9
750.65
907.39
859.72
1,307.23
1,270.58
- -
Basic EPS, GAAP
-75.37
272.5
173.62
216.87
102.52
333.24
220.43
235.3
226.97
215.73
359.64
-18.24
614.05
157.12
1,178.32
1,148.43
- -
Free Cash Flow per Basic Share
76.86
85.98
65.9
65.93
57.31
33.7
72.98
106.09
68.02
101.34
72.59
226.55
226.19
394.35
432.09
509
940.44
Dividend per Share
2,358.16
2,626.63
2,781.04
2,944.85
3,012.17
3,315.59
3,642.56
3,538.9
3,657.19
3,866.34
4,344.46
4,922.99
5,718.86
6,186.99
7,130.46
7,667.14
7,104.49
Book Value per Share
1,393.43
1,586.28
1,807.44
1,889.04
1,857.28
2,153.1
2,238.68
2,468.98
2,651.55
3,020.15
3,414.68
3,545.89
4,472.19
4,751.95
5,208.79
5,827.2
5,298.84
Tangible Book Value per Share
186
186
185
186
185
185
186
186
186
186
186
186
186
185
183
183
183
Basic Weighted Avg Shares
275,312
307,868
326,702
351,886
353,709
365,220
389,690
444,356
445,484
507,794
566,776
630,595
802,755
805,158
857,545
928,962
- -
Sales/Revenue/Turnover
22.76
19.79
14.91
13.2
10.67
18.26
16.07
16.86
16.53
16.47
23.12
23
25.29
30.6
31.54
35.19
- -
Operating Margin (%)
21,135
24,459
26,883
28,301
29,363
31,248
32,895
34,747
34,907
39,320
39,846
44,922
48,569
50,808
52,760
60,463
- -
Depreciation Expense
64,640
49,281
49,240
42,766
24,950
53,863
66,200
8,885
35,348
47,135
104,683
139,626
169,076
158,850
239,244
232,335
- -
Net Income, GAAP
4.63
0.44
1.69
2.76
2.95
10.04
1.76
27.56
17.66
4.76
7.91
3.68
- -
6.35
14.78
18.44
- -
Effective Tax Rate (%)
23.48
16.01
15.07
12.15
7.05
14.75
16.99
2
7.93
9.28
18.47
22.14
21.06
19.73
27.9
25.01
- -
Profit Margin (%)
181,735
202,675
240,422
226,906
197,702
236,296
220,734
223,345
265,920
300,018
341,580
289,409
396,263
420,405
459,634
600,978
514,206
Working Capital
41,694
62,226
73,163
54,781
44,155
37,188
28,874
3
2
10,296
10,754
18,649
15,986
18,457
19,589
18,102
15,780
LT Debt
442,115
489,856
520,074
551,196
560,212
618,389
681,873
664,019
685,745
724,873
813,939
923,022
1,073,847
1,142,581
1,303,862
1,400,889
1,302,179
Total Equity
13.75
11.74
7.9
7.34
5.69
9.43
7.78
2.17
5.49
5.32
13.51
14.74
- -
15.44
17.61
16.96
- -
Return on Invested Capital (%)
17.78
9.72
8.94
7.41
4.26
8.57
9.59
1.22
5.11
6.51
13.26
15.61
- -
15.15
19.94
17.48
- -
Return on Capital (%)
15.86
10.66
9.82
8.03
4.51
9.19
10.24
1.33
5.28
6.74
13.73
16.22
17.09
14.48
19.68
17.22
- -
Return on Common Equity (%)

Capital Structure

HUF

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
7,836
5,752
5,835
LT Borrowings
4,965
1,178
1,173
LT Finance Leases
14,624
14,402
14,607
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
182
182
183
Market Capitalization
1,896,765
1,871,232
1,828,648

Working Capital

HUF

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
641,057
711,788
689,957
Cash, Cash Equivalents & STI
136,621
201,784
149,876
Accounts Receivable, Net
240,327
235,058
254,850
Inventories
215,411
223,982
223,330
Total Current Liabilities
175,242
158,491
175,751
Payables & Accruals
- -
- -
- -
ST Debt
7,836
5,752
5,835
Deferred Revenue
- -
- -
- -

Growth Rates

HUF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.66%
11.54%
7.44%
Free Cash Flow
-298.03%
-602.33%
-2.62%
Net Income, GAAP
48.57%
19.23%
-2.89%
Sales/Revenue/Turnover
10.03%
10.74%
8.33%
Total Cash Common Dividend
45.86%
62.25%
17.7%

Quarterly Revenue

HUF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
203,432
216,261
- -
- -
857,545
2025
224,024
241,485
- -
- -
928,962
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

HUF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
373
382.92
- -
- -
1,307.23
2025
373
283.15
- -
- -
1,270.58
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

HUF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
431.31
- -
- -
432.09
2025
0.01
508.03
- -
- -
509
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Chemical Works of Gedeon Richter Plc (RICHT.BD) engages in the research, development, manufacturing, and marketing of pharmaceuticals worldwide. Founded in 1901 and headquartered in Budapest, Hungary, the company operates through two primary segments: Pharmaceuticals, encompassing Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and Others, including wholesale, retail distribution, and support services. It manufactures approximately 2800 products, including original, generic, biosimilar, and licensed medicines targeting gynaecological, cardiovascular, central nervous system, oncology, neuroscience, anti-inflammatory, antiallergic, antiulcer, tranquillizer, antibacterial, and gastrointestinal therapeutic areas; key offerings include recombinant follicle stimulating hormone (BEMFOLA), proprietary antipsychotics like cariprazine, Panangin, and steroid-based products for women's health, with active pharmaceutical ingredients produced at facilities in Dorog, Debrecen biotechnology plant, and subsidiaries in Russia and Poland. The company maintains manufacturing sites in Budapest and Dorog, Hungary; Debrecen for biopharmaceuticals; Gedeon Richter RUS for solid dosage forms serving CIS countries and Hungary; and Gedeon Richter Polska for tablets and capsules exported to Russia, Belarus, Uzbekistan, Romania, and Ukraine; it conducts operations in over 100 countries, with expanding presence in Western Europe, China, North America, Latin America, and joint ventures such as Richter-Helm in Germany and partnerships in India. Recent developments include a May 2025 strategic investment and collaboration with Granata Bio, acquiring a significant equity stake, securing a board seat, co-developing BEMFOLA for the US fertility market, and entering a royalty agreement for human menopausal gonadotropin, aimed at strengthening US women's health presence; additionally, affiliate Richter BioLogics opened a new cGMP biopharmaceutical facility in September 2024 for sterile injectables, and ongoing CNS collaborations with AbbVie persist into 2025.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Gedeon Richter PLC (GEDSF) Q1 2026 Earnings Call Transcript